Saurashtra News

Advanced Ovarian Cancer Pipeline Report builds understanding of the Limitations and challenges with regard to the development of Advanced Ovarian Cancer | Major Companies – AstraZeneca, Pfizer, Merck,

 Breaking News
  • No posts were found

Advanced Ovarian Cancer Pipeline Report builds understanding of the Limitations and challenges with regard to the development of Advanced Ovarian Cancer | Major Companies – AstraZeneca, Pfizer, Merck,

April 24
10:44 2023
Advanced Ovarian Cancer Pipeline Report builds understanding of the Limitations and challenges with regard to the development of Advanced Ovarian Cancer | Major Companies - AstraZeneca, Pfizer, Merck,

DelveInsight’s, “Advanced Ovarian Cancer Pipeline Insight 2023” report provides comprehensive insights about 60+ companies and 70+ pipeline drugs in the Advanced Ovarian Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Advanced Ovarian Cancer Pipeline Report

 

  • DelveInsight’s Advanced Ovarian Cancer Pipeline report depicts a robust space with 60+ active players working to develop 70+ pipeline therapies for Advanced Ovarian Cancer.

 

  • The leading Advanced Ovarian Cancer Companies include OncoQuest, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, Merck KGaA, Pfizer, Jiangsu HengRui Medicine Co., Ltd., Boehringer Ingelheim, Impact Therapeutics, Inc., Glycotope, Puma Biotechnology, Inc., Bayer, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Daiichi Sankyo, Inc., Astellas Pharma Inc, and others.

 

  • Promising Advanced Ovarian Cancer Pipeline Therapies include Bevacizumab, Durvalumab, Olaparib, Niraparib, ZL-2306 (Nirapairb), Fluzoparib, Paclitaxel, BIBF 1120, Karenitecin, Topotecan, and others.

 

  • Advanced Ovarian Cancer companies and academics are working to assess challenges and seek opportunities that could influence Advanced Ovarian Cancer R&D. The Advanced Ovarian Cancer pipeline therapies under development are focused on novel approaches to treat/improve Advanced Ovarian Cancer.

 

Request a sample and discover the recent breakthroughs happening in the Advanced Ovarian Cancer Pipeline landscape @ Advanced Ovarian Cancer Pipeline Outlook Report

 

Advanced Ovarian Cancer Overview

Advanced Ovarian Cancer means that cancer has spread outside the ovary. It may have spread within the pelvis or abdomen, or further away to other parts of the body such as the lungs. Some women have Advanced Ovarian Cancer when they are first diagnosed, and treatment can cure their cancer. This depends on several factors, including the exact stage of cancer.

 

Recent Developmental Activities in the Advanced Ovarian Cancer Treatment Landscape

 

  • The US Food and Drug Administration (FDA) granted orphan drug designation to mirvetuximab to treat ovarian cancer; mirvetuximab has also secured this designation in the EU.

 

  • In June 2018, the FDA granted mirvetuximab Fast Track designation to treat patients with a medium to high FRα-positive platinum-resistant ovarian cancer who got administered at least one but no more than three prior systemic treatment regimens for whom single-agent chemotherapy is apt as the following line of therapy.

 

  • In August 2021, Sutro Biopharma received Fast Track Designation for STRO-002 by the US FDA for Patients with Advanced Ovarian Cancer.

 

  • In February 2021, the FDA granted a fast-track designation to the DNA-mediated interleukin-12 immunotherapy GEN-1 to treat advanced ovarian cancer patients. Developed using Celsion’s exclusive TheraPlas platform technology, GEN-1 is an IL-12 DNA plasmid vector enclosed in a nanoparticle delivery system, which allows cell transformation followed by persistent, local emission of the IL-12 protein.

 

  • In April 2021, Zentalis Pharmaceuticals announced a clinical collaboration agreement to evaluate its ZN-c3 and GlaxoSmithKline’s (GSK) ZEJULA (niraparib) combination advanced epithelial ovarian cancer patients.

 

  • Stenoparib (2X-121), a unique, small molecule dual-targeted inhibitor of Poly ADP-Ribose Polymerases (PARP 1 and 2) and telomerase maintenance enzymes (Tankyrase 1 and 2), was exclusively in-licensed by Allarity Therapeutics (globally) from Eisai and is currently being evaluated in Phase II clinical trial for advanced ovarian cancer.

 

  • In January 2020, Mereo BioPharma Group and Oncologie entered a global licensing agreement to develop and commercial navicixizumab. Navicixizumab is an anti-DLL4/vascular endothelial growth factor (VEGF) bispecific antibody that is currently being evaluated, in combination with paclitaxel, for the treatment of patients with advanced heavily pretreated ovarian cancer. FDA granted fast track designation to navicixizumab in October 2019.

 

For further information, refer to the detailed Advanced Ovarian Cancer Drugs Launch, Advanced Ovarian Cancer Developmental Activities, and Advanced Ovarian Cancer News, click here for Advanced Ovarian Cancer Ongoing Clinical Trial Analysis

 

Advanced Ovarian Cancer Emerging Drugs Analysis

 

  • Oregovomab: OncoQuest

Oregovomab is a murine IgG against CA 125. Indirect immunization with oregovomab interacts with immune modulating properties of infused paclitaxel and carboplatin resulting in synergistic clinical benefit as observed in a phase 2 trial.  In a randomized Phase 2 clinical trial of 97 patients, treatment with Oregovomab in combination with chemotherapy had demonstrated a highly statistically significant and clinically meaningful outcome for both progression-free and overall survival compared to standard of care chemotherapy (carboplatin and paclitaxel). The risk of progression and of death was reduced by more than 50% when compared to control arm, and safety data showed that oregovomab did not add incremental toxicity to the chemotherapy regimen. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of advanced ovarian cancer.

 

  • SC 10914: Jiangxi Qingfeng Pharmaceutical Co. Ltd.

SC10914 is a highly selective inhibitor of PARP enzymes, including PARP1 and PARP2. SC10914 has a similar structure with olaparib. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Advanced Ovarian Cancer.

 

  • Stenoparib: Allarity Therapeutics

Stenoparib (2X-121) is a unique, small molecule dual targeted inhibitor of Poly ADP-Ribose Polymerases (PARP 1 and 2) and telomerase maintenance enzymes (Tankyrase 1 and 2). Allarity exclusively in-licensed it (globally) from Eisai. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Advanced Ovarian Cancer.

 

Advanced Ovarian Cancer Pipeline Therapeutics Assessment

There are approx. 60+ key companies which are developing the therapies for advanced ovarian cancer. The companies which have their advanced ovarian cancer drug candidates in the most advanced stage, i.e. phase III include, OncoQuest.

 

Find out more about the Advanced Ovarian Cancer Pipeline Segmentation, Therapeutics Assessment, and Advanced Ovarian Cancer Emerging Drugs @ Advanced Ovarian Cancer Treatment Landscape

 

Scope of the Advanced Ovarian Cancer Pipeline Report

 

  • Coverage- Global

 

  • Advanced Ovarian Cancer Companies- OncoQuest, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, Merck KGaA, Pfizer, Jiangsu HengRui Medicine Co., Ltd., Boehringer Ingelheim, Impact Therapeutics, Inc., Glycotope, Puma Biotechnology, Inc., Bayer, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Daiichi Sankyo, Inc., Astellas Pharma Inc, and others.

 

  • Advanced Ovarian Cancer Pipeline Therapies- Bevacizumab, Durvalumab, Olaparib, Niraparib, ZL-2306 (Nirapairb), Fluzoparib, Paclitaxel, BIBF 1120, Karenitecin, Topotecan, and others.

 

  • Advanced Ovarian Cancer Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Dive deep into rich insights for drugs for Advanced Ovarian Cancer Pipeline Companies and Therapies, click here @ Advanced Ovarian Cancer Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Advanced ovarian cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Advanced ovarian cancer – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Advanced ovarian cancer Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Oregovomab: OncoQuest
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. EP0057: Ellipses Pharma
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. DS-6000a: Daiichi Sankyo Company
  17. Drug profiles in the detailed report…..
  18. Preclinical and Discovery Stage Products
  19. Drug name: Company name
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Advanced ovarian cancer Key Companies
  23. Advanced ovarian cancer Key Products
  24. Advanced ovarian cancer- Unmet Needs
  25. Advanced ovarian cancer- Market Drivers and Barriers
  26. Advanced ovarian cancer- Future Perspectives and Conclusion
  27. Advanced ovarian cancer Analyst Views
  28. Advanced ovarian cancer Key Companies
  29. Appendix

 

Got Queries? Find out the related information on advanced ovarian cancer Mergers and acquisitions, advanced ovarian cancer Licensing Activities @ Advanced Ovarian Cancer Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/